Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results

01.11.2023 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding restructuring of operations and workforce reduction, and ...

Related Keywords

United States ,California ,Brisbane ,Queensland ,Australia ,American ,Lang Schwarz ,Gregory Davis ,D Mark Mcclung ,Jason Fontenot ,Kamy Pooler ,Twitter ,Safety Monitoring Committee ,American Society For Hematology Annual Meeting ,Novartis ,Exchange Commission ,Head Of Research ,Pfizer ,Head Of Technology ,European Society Of Gene ,Linkedin ,Executive Vice President ,Chief Operating Officer ,Senior Vice President ,Chief Scientific Officer ,Vice President ,Genome Engineering Design ,Epigenetic Regulation Programs ,European Society ,Cell Therapy ,Phelan Mcdermid Syndrome ,Regenerative Medicine Advanced Therapy ,Orphan Drug ,Fast Track ,Safety Monitoring ,American Society ,Hematology Annual ,Cash Equivalents ,Financial Guidance ,Securities Biopharma Symposium ,London Healthcare Conference ,Discuss Third Quarter ,Annual Report ,Quarterly Report ,Operations Data ,Balance Sheet Data ,Sangamo Therapeutics Stock ,Sangamo Therapeutics Chart ,Angamo Therapeutics Kurs ,Angamo Therapeutics Aktie ,